Hair Loss Conditions

Chronic Telogen Effluvium Tracking: Document Long-Term Diffuse Shedding

February 23, 20266 min read1,200 words

Chronic telogen effluvium affects predominantly perimenopausal women and is often confused with female-pattern androgenetic alopecia (AGA). Monthly density readings over 12 or more months create the longitudinal record that distinguishes CTE from AGA and guides treatment decisions, turning a frustrating diagnostic process into a data-driven one.

This content is for informational purposes only and does not constitute medical advice.

What Makes Chronic Telogen Effluvium Different

Telogen effluvium occurs when a larger-than-normal percentage of hair follicles enter the telogen (resting) phase simultaneously, leading to diffuse shedding. Acute telogen effluvium has a clear trigger and resolves within 6 months. Chronic telogen effluvium (CTE) persists beyond 6 months and follows a fluctuating pattern that can last years.

FeatureAcute TEChronic TEFemale AGA
DurationLess than 6 monthsMore than 6 monthsProgressive, permanent
Shedding patternSingle episodeFluctuating episodesGradual, steady
DistributionDiffuse, all zonesDiffuse, all zonesCrown and part line
TriggerIdentifiable (illness, stress, surgery)Often no clear triggerGenetic, hormonal
RecoveryUsually completeVariable, often resolvesDoes not reverse without treatment
Density pattern over timeDrops then recoversFluctuates up and downSteady downward trend

The challenge is that CTE and early female AGA can look identical at a single point in time. Only the density pattern over months reveals which condition is present.

Step 1: Start Monthly Density Tracking Immediately

The moment you suspect CTE, begin monthly density readings with myhairline.ai. The sooner you start tracking, the sooner the density pattern becomes clear enough for a definitive assessment.

Capture all scalp zones at each session:

  1. Frontal hairline
  2. Mid-scalp along the part line
  3. Crown/vertex area
  4. Temporal regions (both sides)
  5. Occipital area (back of head, typically unaffected in CTE)

The occipital reading is your internal control. In CTE, this area should maintain stable density. In diffuse AGA, even occipital density may decline slightly.

Step 2: Log Shedding Episodes and Potential Triggers

CTE often presents with episodic increases in shedding. Some weeks you may notice significantly more hair fall, followed by periods of relative normalcy. Logging these episodes alongside your density readings creates the fluctuating pattern that characterizes CTE.

For each shedding episode, record:

  • Start date and approximate duration
  • Estimated daily hair count if possible (normal shedding is 50 to 100 hairs per day)
  • Any concurrent events: illness, stress, travel, medication changes, menstrual cycle phase
  • Dietary changes or supplement additions

Over 6 to 12 months of tracking, patterns may emerge. Some women with CTE notice shedding episodes that correlate with specific triggers, while others see no consistent correlation.

Step 3: Track Blood Work Alongside Density Data

CTE can be associated with underlying conditions that affect hair cycling. Common contributors include thyroid dysfunction, iron deficiency, vitamin D insufficiency, and hormonal changes. Work with your physician to test for these factors.

Lab TestRelevant RangeConnection to CTE
FerritinBelow 40 ng/mL associated with sheddingIron stores directly affect hair follicle cycling
TSHOutside 0.5 to 4.5 mIU/L rangeThyroid dysfunction disrupts hair growth phase
Vitamin DBelow 30 ng/mL is insufficientLow levels associated with telogen effluvium
Estradiol/ProgesteronePerimenopausal fluctuationsHormonal shifts trigger telogen effluvium
CBC with differentialAnemia indicatorsSystemic health affects hair cycling

Log your blood work results and dates in your myhairline.ai treatment timeline. When you correct a deficiency (for example, raising ferritin from 15 to 70 ng/mL), the density readings after correction show whether that intervention produced a measurable response.

Step 4: Differentiate CTE from Female AGA Using Your Data

After 6 to 12 months of tracking, your density timeline should reveal one of two patterns.

CTE pattern: Density fluctuates. You see dips during shedding episodes followed by partial or full recovery. The overall trend line is roughly flat or shows a sawtooth pattern. Affected zones are diffuse across the entire scalp. Occipital density remains stable.

Female AGA pattern: Density shows a steady downward trajectory without the episodic fluctuation. The crown and part line thin more than the sides and back. The overall trend is consistently declining.

Export your 6 to 12 month density report as a PDF and bring it to your dermatologist. This longitudinal data is significantly more useful than a single office visit assessment. The density trend over time is the most reliable non-invasive method for distinguishing these two conditions.

Step 5: Monitor Treatment Response Over Time

If your dermatologist prescribes treatment, track the response with the same monthly protocol. Common treatments for CTE include:

Minoxidil: Applied topically, 40 to 60% of users see moderate improvement. For CTE, minoxidil may help maintain density during shedding episodes even if the underlying cause has not been addressed. Expect 4 to 6 months before density changes become measurable.

Nutritional correction: If blood work revealed deficiencies, correcting them (iron supplementation, vitamin D, thyroid medication) should show density stabilization within 3 to 6 months.

Stress management: If shedding episodes correlate with stress periods, interventions targeting stress may reduce episode frequency. Track whether episodes become less frequent or less severe over time.

PRP therapy: At $500 to $2,000 per session, PRP can increase density by 30 to 40% in clinical studies. For CTE patients, PRP may help support follicles during vulnerable periods. Track density before and after each session.

Step 6: Establish a Long-Term Monitoring Plan

CTE can persist for years before resolving. A long-term monitoring plan prevents you from losing sight of gradual changes that are only visible in retrospect.

After the initial 12 months of monthly tracking, you can reduce frequency to every 6 to 8 weeks if your density has stabilized. If a new shedding episode begins, return to monthly readings immediately.

The long-term data also protects against diagnostic drift. If CTE transitions to or coexists with female AGA (which can happen), the density trend change will appear in your tracking data before it becomes obvious clinically.

Build Your CTE Evidence Record

Chronic telogen effluvium is one of the most difficult hair loss conditions to diagnose and manage precisely because it requires longitudinal data. Monthly tracking with myhairline.ai gives you and your dermatologist the evidence needed to distinguish CTE from AGA, monitor treatment response, and make informed decisions.

Start your free density baseline at myhairline.ai/analyze today.

This article is for informational purposes only and does not constitute medical advice. Consult a board-certified dermatologist or hair restoration specialist for personalized treatment recommendations.

Frequently Asked Questions

Acute telogen effluvium lasts less than 6 months and usually follows a specific trigger (illness, surgery, childbirth, medication change). Chronic telogen effluvium persists beyond 6 months, often without a clear ongoing trigger. CTE involves fluctuating shedding episodes rather than a single shedding event, and density tracking over 12 or more months is needed to distinguish it from female-pattern hair loss.

Ready to Assess Your Hair Loss?

Get an AI-powered Norwood classification and personalized graft estimate in 30 seconds. No downloads, no account required.

Start Free Analysis